Immunovant, Inc.
IMVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $522 | $599 | $714 | $375 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $2 | $2 | $3 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $50 | $51 | $51 | $36 |
| Total Curr. Assets | $574 | $652 | $768 | $413 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $9 | $9 | $8 | $8 |
| Total NC Assets | $9 | $10 | $9 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $583 | $661 | $776 | $421 |
| Liabilities | – | – | – | – |
| Payables | $7 | $8 | $18 | $20 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $56 | $45 | $51 | $48 |
| Total Curr. Liab. | $63 | $53 | $69 | $68 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $63 | $53 | $69 | $68 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,487 | -$1,360 | -$1,240 | -$1,133 |
| AOCI | $1 | $2 | $1 | $2 |
| Other Equity | $2,005 | $1,967 | $1,945 | $1,483 |
| Total Equity | $520 | $609 | $707 | $353 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $583 | $661 | $776 | $421 |
| Net Debt | -$522 | -$599 | -$714 | -$375 |